Regulatory environment for novel therapeutic development in mitochondrial diseases. Issue 2 (4th January 2021)

• Record Type: Journal Article
• Authors: Hirano, Michio; Berardo, Andres; Barca, Emanuele; Emmanuele, Valentina; Quinzii, Catarina; Simpson, Camilla V.; Engelstad, Kristin; Rosales, Xiomara Q.; Thompson, John L. P.
• Is Part Of: Journal of inherited metabolic disease. Volume 44:Issue 2(2021)
• Page Start: 292
• Page End: 300
• Publication Date: 2021-01-04
• Subjects: Food and Drug Administration -- mitochondrial disease -- therapy -- thymidine kinase 2 -- TK2; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jimd.12353
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: At present, there is just one approved therapy for patients with mitochondrial diseases in Europe, another in Japan, and none in the United States. These facts reveal an important and significant unmet need for approved therapies for these debilitating and often fatal disorders. To fill this need, it is critical for clinicians and drug developers to work closely with regulatory agencies. In the United States, mitochondrial disease patients and clinicians, the United Mitochondrial Disease Foundation, and pharmaceutical industry members have engaged with the Food and Drug Administration to educate each other about these complex and heterogeneous diseases and about regulatory requirements to obtain approvals for novel therapies. Clinical development of therapies for rare diseases has been facilitated by the 1983 US Orphan Drug Act (ODA) and similar legislation in Japan and the European Union. Further legislation and regulatory guidance have expanded and refined regulatory flexibility. While regulatory and financial incentives of the ODA have augmented involvement of pharmaceutical companies, clinicians, with patient advocacy groups and industry, need to conduct natural history studies, develop clinical outcome measures, and identify potential supportive surrogate endpoints predictive of clinical benefit, which together are critical foundations for clinical trials. Thus, the regulatory environment for novel therapeutic development is conducive and offers flexibility for mitochondrial diseases. Nevertheless, flexibility does not mean lower standards, as well‐controlled rigorous clinical trials of high quality are still required to establish the efficacy of potential therapies and to obtain regulatory agency approvals for their commercial use. This process is illustrated through the authors' ongoing efforts to develop therapy for thymidine kinase 2 deficiency.